Annals of Hematology最新文献

{"title":"The role of the immune system in progressive multifocal leukoencephalopathy: a comparative analysis of two cases following autologous and allogeneic hematopoietic stem cell transplantation.","authors":"Biancamaria Mandelli, Roberta Mazzarella, Andrea Corbingi, Elettra Ortu La Barbera, Salvatore Perrone, David Fanciullo, Martina Lorenzon, Giada Pacitto, Natalia Cenfra, Sergio Mecarocci, Sofia Asioli, Alessandro Pulsoni","doi":"10.1007/s00277-025-06258-5","DOIUrl":"10.1007/s00277-025-06258-5","url":null,"abstract":"<p><p>Progressive multifocal leukoencephalopathy (PML) is a rare, subacute demyelinating disorder of the central nervous system (CNS) caused by the JCV. In immunosuppressed hosts, PML is caused by reactivation of a latent infection rather than primary exposure. Hematological patients, particularly post-transplant, presenting with worsening neurological symptoms should promptly consider PML in the differential diagnosis. The rarity of PML after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) and the absence of a universally effective therapy represents a clinical challenge. Here, we present two cases of PML developed after autologous and allogeneic HSCT, with completely different outcomes dependent on the patients' clinical backgrounds and the level of immune system competence which is the key factor in determining either the onset or viral clearance of the infection.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3505-3510"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Galectin-9: A double-edged sword in Acute Myeloid Leukemia\".","authors":"Omolbanin Sargazi Aval, Ali Ahmadi, Ali Jihad Hemid Al-Athari, Hamed Soleimani Samarkhazan, Fatemeh Sotudeh Chafi, Marjan Asadi, Mohammad Hossein Mohammadi, Mojtaba Aghaei","doi":"10.1007/s00277-025-06387-x","DOIUrl":"10.1007/s00277-025-06387-x","url":null,"abstract":"<p><p>Acute Myeloid Leukemia (AML) presents a formidable challenge in the realm of hematologic malignancies, characterized by the unregulated proliferation of myeloid progenitor cells, leading to severe disruptions in normal hematopoiesis. This review examines the multifaceted role of Galectin-9, a crucial glycan-binding protein in the pathophysiology of AML, emphasizing its potential as both a prognostic biomarker and a therapeutic target. Recent insights into the molecular underpinnings of AML, particularly those involving genetic mutations and cytogenetic abnormalities, illuminate the complex landscape of this disease, where patient outcomes are significantly influenced by individual biological markers. Galectin-9, initially recognized for its involvement in fundamental biological processes such as cell proliferation and immune modulation, has emerged as a pivotal molecule in AML, with expression levels correlating with leukemic cell behavior and clinical prognosis. This review consolidates the extensive literature on Galectin-9, elucidating its role in leukemic transformation and the therapeutic implications of manipulating this pathway. By investigating the intricate relationship between Galectin-9 and AML, we aim to provide a comprehensive understanding that could lead to innovative strategies for managing this aggressive malignancy, offering hope for improved survival outcomes through targeted therapeutic interventions.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3077-3090"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinician characteristics associated with use of risk assessment models for venous thromboembolism and bleeding in hospitalized patients.","authors":"Alexander J B Bulteel, Kevin Barnum, Siddhant Datta, Laura E Dodge, Leslie Lake, Pavania Elavalakanar, Barbara D Lam, Rushad Patell","doi":"10.1007/s00277-025-06380-4","DOIUrl":"10.1007/s00277-025-06380-4","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3531-3536"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of chronic-phase CML in later lines: a Hong Kong consensus recommendation.","authors":"Carol Yuk Man Cheung, Chung Yin Ha, Bonnie Kho, Chi Kuen Lau, June Sze Man Lau, Shek Ying Lin, Vivien Wai Man Mak, Raymond Siu Ming Wong, Yok Lam Kwong","doi":"10.1007/s00277-025-06416-9","DOIUrl":"10.1007/s00277-025-06416-9","url":null,"abstract":"<p><p>Chronic myeloid leukemia (CML) usually requires long-term therapy with tyrosine kinase inhibitors (TKIs). While these agents have markedly advanced the clinical management and prognosis of CML, a subset of patients experience treatment resistance or suboptimal response, necessitating multiple lines of TKI therapy. Few treatment options exist for patients who are resistant or intolerant to first- and second-line therapies. To provide guidance for the management of patients in chronic-phase failing at least two lines of treatment, a literature review followed by consensus generation from an expert panel with a modified Delphi process was conducted. This was followed by a meeting in person and subsequent online iterations for the establishment of a list of consensus guidelines. Consensus was defined as ≥ 75% of respondents selecting either 'accept completely' or 'accept with some reservation'. Overall, 17 statements were formulated covering five topics - defining treatment failure and acceptable treatment response, in terms of efficacy and intolerance; sequencing therapy to prevent disease progression and improve quality of life; managing patients with broad resistance, specific mutations, and risk of cardiovascular events; considering timing of cytogenetic or molecular response; and mitigating risk when using novel therapies and allogeneic hematopoietic stem cell transplantation. These comprehensive, evidence-based recommendations will assist clinicians in managing their patients with CML in third and later lines of treatment.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3091-3101"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zinc level and its impact on the phenotype of sickle cell disease.","authors":"Ilham Youssry, Mona El-Ghamrawy, Eman R Youness, Nahla A Mohamed, Yasmeen Mohammed Mahmoud Selim","doi":"10.1007/s00277-025-06429-4","DOIUrl":"10.1007/s00277-025-06429-4","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3213-3221"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144214747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term follow-up of autologous hematopoietic cell transplantation for diffuse large B cell lymphoma in the rituximab era: real‑world data from a retrospective single‑center analysis.","authors":"Jiangtao Li, Fei Zhao, Long Qian, Jingjing Yin, Yazi Yang, Jiefei Bai, Chunli Zhang, Ting Wang, Ru Feng, Hui Liu","doi":"10.1007/s00277-025-06430-x","DOIUrl":"10.1007/s00277-025-06430-x","url":null,"abstract":"<p><p>Autologous stem cell transplantation (ASCT) is the standard treatment for diffuse large B-cell lymphoma (DLBCL) in certain circumstances. However, the risk factors for ASCT outcomes remain elusive. We analyzed data from 141 patients with DLBCL who underwent first ASCT in the past decade, including 19 with pre-existing autoimmune disorders (ADs). We focus on the clinical characteristics and their potential predictive roles for the long-term transplant prognosis. With a median follow-up of 50 months (interquartile range, 26.3 to 128), progression-free survival (PFS) and overall survival (OS) at 3 years were 82.8% and 90.2%, respectively. Deaths after ASCT were predominantly caused by lymphoma relapse (73.3%). Notably, ADs history was independently associated with an increased risk of all-cause mortality (Hazard Ratio [HR]: 8.38, P = 0.014) and lymphoma relapse (HR: 6.67, P = 0.026). Furthermore, disease status before ASCT, COO subtypes, lactate dehydrogenase level at diagnosis and relapse after chemotherapy were also identified as prognostic factors for both PFS and OS. These findings demonstrate ASCT as a viable treatment option for eligible patients with high-risk DLBCL and highlight the need for increased attention to lymphoma with pre-ADs.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3423-3431"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological features and prognostic factors of AIDS-related lymphoma: a retrospective single-center study in China.","authors":"Ying Liang, Jing Chang, Yuxue Gao, Lin Sun, Zhujun Yue, Lingjia Meng, Caiping Guo, Yulin Zhang","doi":"10.1007/s00277-025-06424-9","DOIUrl":"10.1007/s00277-025-06424-9","url":null,"abstract":"<p><p>AIDS-related lymphoma (ARL) is a leading cause of mortality among people living with HIV (PLWH), characterized by distinct clinicopathological features and a generally poor prognosis. However, comprehensive studies on ARL remain limited. This study aimed to evaluate the clinicopathological characteristics, immune status, and Epstein-Barr virus (EBV)/HIV viral loads in PLWH diagnosed with lymphoma, and to assess their prognostic significance. A retrospective analysis was conducted on 130 ARL cases diagnosed between 2017 and 2024. The cohort included 56 Burkitt lymphoma (BL), 51 diffuse large B-cell lymphoma (DLBCL), 9 Hodgkin lymphoma (HL), 8 plasmablastic lymphoma (PBL), and 6 T/NK cell lymphoma patients. The median age was 39 years, with 94.6% of patients being male. The 2-year overall survival (OS) rate was 50.6%, with HL showing the highest survival rate (85.7%) and BL the lowest (43.8%). Univariate analysis identified several factors significantly associated with poorer OS in non-Hodgkin lymphoma (NHL), including CD4 + T cell count < 200 cells/µL, presence of B symptoms, Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2, elevated lactate dehydrogenase (LDH), Ann Arbor Stage III/IV disease, > 1 site with extranodal involvement, and bone marrow involvement (all P < 0.05). Multivariate analysis revealed that CD4 + T cell count < 200 cells/µL (HR: 2.085, P = 0.026) and elevated LDH (HR: 0.378, P = 0.005) were independent prognostic factors. In conclusion, NHL, particularly BL and DLBCL, is the predominant lymphoma subtype among PLWH. Severe immunodeficiency and elevated LDH may serve as effective prognostic factors for predicting OS in patients with AIDS-related NHL.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3411-3422"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-curative therapies and their impact on the prognosis of patients with myelodysplastic syndromes- a retrospective matched-pairs analysis.","authors":"Katharina Anna Rauhe, Annika Kasprzak, Felicitas Schulz, Kathrin Nachtkamp, Corinna Strupp, Andrea Kündgen, Sascha Dietrich, Karin Mayer, Katharina S Götze, Wolf-Karsten Hofmann, Aristoteles Giagounidis, Norbert Gattermann, Ulrich Germing","doi":"10.1007/s00277-025-06485-w","DOIUrl":"10.1007/s00277-025-06485-w","url":null,"abstract":"<p><p>Allogeneic stem cell transplantation (SCT) remains the only curative therapy for patients with high-risk myelodysplastic syndromes (MDS). Due to age, comorbidities, or lack of urgency, many receive only palliative therapies to improve quality of life. Some patients remain untreated due to a lack of symptoms or low progression risk. Data on the impact of palliative therapies on overall survival (OS) and leukemia-free survival (LFS) are limited. Using the Düsseldorf MDS Registry, we compared outcomes of patients receiving red blood cell transfusions (RBCT) alone to the outcome of patients receiving RBCT combined with iron chelation therapy (ICT), erythropoietin (EPO), antithymoglobulin (ATG), or lenalidomide (LENA). Matched-pairs analysis was conducted using age, gender, and prognostic scores (Revised International Prognostic Scoring System or Chronic Myelomonocytic Leukemia-specific Prognostic Scoring System). ICT-treated patients (n = 85) had significantly improved OS (70 vs. 21 months, p < 0.001) and lower 5-year AML progression (3.5% vs. 28.2%, p < 0.001). Similar benefits were seen with EPO (n = 210; OS: 63 vs. 24 months, p < 0.001; AML: 5.7% vs. 19%, p = 0.007) and LENA (n = 30; OS: 92 vs. 57 months, p = 0.049; AML: 0% vs. 16.7%, p = 0.024). ATG (n = 11) showed no significant improvement in OS (79 vs. 64 months) or AML progression (0% vs. 18.2%). While recognizing the limitations of matched-pairs analysis versus randomized trials, our findings indicate a survival benefit from ICT, EPO, or LENA versus RBCT alone. The year of diagnosis did not independently affect OS or LFS. These results support the use of selected palliative therapies to improve long-term outcomes in MDS patients. KEY POINTS: Treating patients with myelodysplastic syndromes with non-curative therapies beyond red blood cell transfusions like iron chelation therapy, erythropoietin, or lenalidomide has a positive impact on overall survival and leukemia-free survival.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3281-3288"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144504741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective cohort study of chimeric antigen receptor T-Cell therapy in follicular lymphoma patients with or without histological transformation.","authors":"Jingjing Wang, Liangyu Zeng, Xiao Ma, Ting Xu, Depei Wu, Caixia Li","doi":"10.1007/s00277-025-06428-5","DOIUrl":"10.1007/s00277-025-06428-5","url":null,"abstract":"<p><strong>Background: </strong>Follicular lymphoma (FL), one of the most common indolent lymphomas, is still classified as an incurable disease. Adverse outcomes in FL frequently occur in patients who experience early relapse or histological transformation to aggressive lymphoma. Chimeric antigen receptor T-cell therapy (CAR-T) has received approval for the treatment of relapsed/refractory B-cell lymphoma.</p><p><strong>Methods: </strong>This retrospective study presents the clinical characteristics and treatment follow-up of 26 patients with transformed or relapsed/refractory FL who received CAR-T therapy. It evaluates the efficacy of CAR-T and assesses treatment lines, LDH levels, remission status before treatment, and the histological transformation of their prognostic impact.</p><p><strong>Results: </strong>Among the 14 transformed FL patients, there was one treatment-related death, the overall response rate (ORR) was 92.0%, with a 2-year progression-free survival (PFS) rate of 66.7% and an overall survival (OS) rate of 73.3%. For the 12 relapsed/refractory FL patients, the ORR was 100.0%, with a 2-year PFS rate of 75.0% and an OS rate of 100.0%, which is higher than that for transformed FL. A favorable remission state before CAR-T treatment correlated with improved PFS (P = 0.009). Compared to transformed patients, those with relapsed/refractory FL exhibited better OS following CAR-T treatment (P = 0.04).</p><p><strong>Conclusion: </strong>CAR-T therapy shows significant efficacy and safety for treating relapsed/refractory follicular lymphoma and transformed lymphoma. Further research should focus on identifying prognostic factors, extending remission duration, and preventing recurrence.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3309-3317"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relapses and outcomes of systemic chemo-free therapies combined with intravitreous methotrexate in isolated primary vitreoretinal lymphoma: an analysis based on two prospective cohort studies.","authors":"Hongyun Chen, Zhe Zhuang, Xiao Zhang, Daobin Zhou, Meifen Zhang, Wei Zhang","doi":"10.1007/s00277-025-06414-x","DOIUrl":"10.1007/s00277-025-06414-x","url":null,"abstract":"<p><p>The definitive therapeutic paradigm for primary vitreoretinal lymphoma (PVRL) remains controversial, with ongoing debates surrounding the comparative efficacy of localized ocular therapy, high-dose systemic chemotherapy, and combined-modality approaches. The benefit of systemic administration of methotrexate is unambiguous and severe adverse events related to intense chemotherapy are reported. Immunomodulators such as lenalidomide and Bruton's tyrosine kinase (BTK) inhibitors, like zanubrutinib, have not been explored for their safety and efficacy as first-line treatments for PVRL. This study aimed to analyze the safety and efficacy of chemo-free combination regimens in newly diagnosed PVRL patients. In our study, systemic chemo-free regimens were administrated as induction therapy, including the ZR regimen (zanubrutinib and rituximab), and the R2 regimen (lenalidomide and rituximab). Of the 44 patients, 41 (93.2%) achieved complete remission following induction therapy. No severe systemic adverse events were observed. After a median follow-up of 25.1 months, 17 patients (38.6%) suffered relapses, including one intraocular relapse and 17 brain relapses. By the final follow-up, 5 patients (11.4%) had died from disease progression. The median PFS and OS were 22.1 and 71.5 months, respectively. The ZR regimen demonstrated a longer PFS compared to the R2 regimen (10.9 months vs. not reached; log-rank test, P = 0.00044), positioning it as a promising treatment option for PVRL patients.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":"3403-3410"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12283856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}